Agenda & Learning Objectives

Participants in this program will be able to:
  • Review the accomplishments of PACE
  • Examine the key findings of the Genetics, Environmental and Microbial (GEM) project
    • Consider the future of research in IBD
    • Discuss the effect on clinical practice
    • Appraise dietary therapy in IBD
  • Examine the key findings of Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects (IMAGINE)
    • Explore the effects on practice
    • Review the Strategy for Patient Oriented Research (SPOR)
    • Consider the status and integration of patient oriented research
  • Integrate basic science and clinical practice by participation in a choice of workshop to:
    • Examine pandemics, practice and policy in IBD, or
    • Discuss the microbiome, or
    • Review IBD research in the COVID-19 world, or
    • Reflect on new era, new science, new antibodies, or
    • Consider how patients make decisions regarding therapy

NOTE: Junior Investigator Award – Please go to the Call for Abstracts page on the registration site
 

Time Title/Topic Speakers
11:00 EST 0.1 Welcome: Nurse of the Year Award, Physician of the Year Award Mina Mawani, Crohn's and Colitis Canada CEO
11:05 EST 0.2 Opening Remarks – Welcome, program objectives
CO-CHAIRS:
Remo Panaccione &
Hillary Steinhart
11:10 EST PACE Turns 4: Highlights and Accomplishments Geoffrey Nguyen

Session I: GEM Update and How it Will Affect Practice

Primary objective: To review the data that has been generated from these studies and the implications and tools arising from the research.

SESSION CHAIR:
Laura Targownik
11:30 EST Plenary Presentation
1.1 Genetics, Environmental and Microbial (GEM) Project Update
Session Objectivives:
  • Provide an overview of where we were and where we are
  • Summarize key findings and how they will shape future research
  • Summarize key findings and how they may change clinical practice
Ken Croitoru
11:50 EST Plenary Presentation
1.2 Diet and IBD
Session Objectives:
  • Provide an update on key findings relating to dietary factors in IBD
  • Outline what science tells us about how diet should be used to treat patients with IBD

Lindsey Albenberg
University of Pennsylvania
12:10 EST Ask-the Expert Panel Session SESSION CHAIR:
Laura Targownik
PANEL:
Lindsey Allenberg, Ken Croitoru, Maitreyi Raman, Eytan Wine
12:25
EST
1.3 Meeting of the Minds Junior Investigator Award Presentation
MODERATOR:
Remo Panaccione
Junior Investigator TBA
12:45 EST
Refreshment Break (10 mins)
 

Session II: IMAGINE Update and How it Will Affect Practice

Primary objective: To review the data that has been generated from these studies and the implications and tools arising from the research.

SESSION CHAIR: Charles Bernstein
12:55 EST Plenary Presentation
2.1 Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects (IMAGINE) Update
Session Objectives:
  • Provide an update on progress to date
  • Summarize key findings at year 3
Paul Moayyedi
13:15 EST Plenary Presentation
2.2 Strategy for Patient Oriented Research (SPOR) Update
Session Objectives:
  • Where are we in integrating patient oriented research (POR) in IBD?
  • Overview of the value of POR
Deborah Marshall
13:35 EST Ask-the Expert Panel Session SESSION CHAIR:
Charles Bernstein
PANEL:
Deborah Marshall, Paul Moayyedi, Laura Targownik, Sandra Zelinsk
13:50 EST
2.3 Rising Star Award Plenary Presentation
MODERATOR:
Kate Lee
Rising Star TBA

Session III: Workshops – Hot Topics from Bench to Clinic to Policy (30 mins)

  • The number of breakout rooms per topic will be determined by enrolment
  • Delegate attends choice of one 30-minute workshop
  • Facilitators to collaborate on creation of workshop presentation:
    • Each facilitator will moderate one session of 30-minutes either separately in tandem with co-developer depending on final enrolment numbers for workshop (Maximum 30 per room)
14:10 EST Workshop
3.1 IBD: Pandemics, Practice and Policy
Session Objectives:
  • Review the most up-to-date Public Health policies from the Government of Canada
  • Review the up-to-date recommendations from the CCC COVID-19 Task force
  • Consider how the IBD clinical and research communities can plan for the next pandemic
Eric Benchimol

Jennifer Jones

 
Workshop
3.2 Microbiome
Session Objectives: 
  • Provide updates on the state of microbiome research in IBD
  • Discuss the microbiome as a potential therapeutic target in IBD
Kathy McCoy

Michael Surette
Workshop
3.3 IBD Research in the COVID-19 World
Session Objectives:
  • Review key research findings regarding COVID and IBD
  • Discuss the gaps in our understanding of COVID and IBD that need to be on future research agendas
Gilaad Kaplan

Nicola Jones - TBC
Workshop:
3.4 New Era, New Science, New Antibodies
Session Objectives:
  • Review the latest understanding of TDM with old and new biologic agents
  • Discuss novel approaches to understanding TDM (modelling, predictive models, machine learning)
Waqqas Afif

Niels Vande Casteele
  Workshop:
3.5 How Patients Make Decisions Regarding Therapy
Session Objectives:
  • Discuss key concepts in how patients make decisions.
  • Discuss the concepts of shared decision making
Deborah Marshall

Sandra Zelinsky
14:40 EST 4.0 Research Leadership Award & Presentation MODERATOR:
Mina Mawani
Research Leadership TBA
15:00 EST Closing Remarks and Program Evaluation CO-CHAIRS: 
Remo Panaccione & Hillary Steinhart

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.